"Change of Control." It's a phrase that alliance professionals are familiar with. However, reading a contractual term and experiencing it can be quite different. How does an alliance leader navigate the difficult discussion about an acquisition? How can the partner be assured of continuity during an integration? What are the challenges that must be overcome to maintain the health of the alliance?
On January 3rd, 2019, Bristol Myers Squibb announced the acquisition of Celgene Corporation. After the initial shock, Celgene's global alliance leaders immediately engaged partners, such as DarwinHealth, to provide much needed assurances. The journey following this first conversation was not the same for every partner. But partnerships that are strong and successful, two and a half years later, illustrate the value of alliance professionals who built opportunities through an integration to overcome the changes, challenges, and concerns.
Join this discussion to learn more about:
Nisha Zaidi, PhD MSc
Executive Director, R&ED Alliances Strategy & Business Development
Bristol Myers Squibb
Nisha is an Executive Director in Research & Early Development Alliances at Bristol Myers Squibb, a global pharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Nisha serves as a strategic alliance leader responsible for building and optimizing relationships and driving decision-making to ensure long-term sustainability of the Bristol Myers Squibb pipeline through combined internal and external innovation. In her current role, Nisha focuses on maximizing the value of strategic global partnerships, leading company integrations, and mentoring and advising alliance leaders through the life cycle of an alliance, to uphold Bristol Myers Squibb as a partner of choice.
With more than 20 years in the industry, Nisha has worked across Business Development & Global Alliances, Medical Affairs, and Research and Development. Nisha started off her career at Sanofi as a scientist before moving into Medical Affairs. Later at Celgene, Nisha led U.S. drug launches as a Medical lead before joining Global Alliances.
Nisha holds an undergraduate degree from Rutgers University and a master's degree and PhD from the University of Medicine and Dentistry of New Jersey.
Dr. Gideon Bosker
Co-founder & CEO
Gideon Bosker, MD, the co-founder and CEO of DarwinHealth™, brings to this "precision-focused" organization the knowledge, principles, and aspirations nurtured during his 15-year career as an academic scholar and clinician.
While a faculty member at the Yale University School of Medicine and Oregon Health Sciences University, Dr. Bosker authored and/or or edited multiple core textbooks and journals in clinical medicine and pharmacotherapeutics among them, Pharmatecture: Minimizing Medications to Maximize Results, The Manual of Emergency Medicine Therapeutics, Clinical Consensus Reports, The Textbook of Primary and Acute Care Medicine, The QuickConsult Manual of Primary Care Medicine, Geriatric Emergency Medicine, and Pills that Work, Pills that Don't.
Under his direction over the past 10 years, as Founder and CEO of CMEducation Resources, this globally-focused company has produced award-winning, live and digitally-based independent medical education programming in the fields of clinical oncology, biologics-based therapy, genomics-driven precision cancer medicine, diabetes, thrombosis, neurodegenerative disease, obesity, cardiovascular disease, medical diagnostics, genetic screening, and metabolic disorders. These multi-platform initiatives, deploying proprietary technologies and reaching tens of thousands of physicians worldwide, have been implemented under the sponsorship of leading biopharmaceutical and diagnostics companies, including Bayer Healthcare, Pfizer, Bristol Myers Squibb, Genentech, Roche, Daiichi Sankyo, Ipsen, Novo Nordisk, Astra Zeneca, Eisai, Sanofi, Regeneron, Amgen, Genzyme, Natera, Teva, and Quest.
His leadership roles at both DarwinHealth™ and CMEducation have been instrumental in galvanizing an international network of the world's leading scientists, clinical investigators, strategists, and industry leaders who share a commitment for advancing the frontiers and foundations of cancer medicine–as well as other critical disease states with unmet therapeutic needs–based on scientifically rigorous and innovative discoveries and technologies.